Multiple myeloma highlights from ASCO 2016: monoclonal antibodies and oral proteasome inhibitors
Why do charities need to keep funding research into leukemia and blood cancer in general?
COMy 2017: Day 1 discussion on progress in multiple myeloma, patient advocacy and drug costs
Arnon Nagler et al.
Ibrutinib in treatment for refractory or relapsed CLL
Choosing treatment options for CLL and combining novel drugs